Examination of the role of Stat3 through the use of the CPA7 [40] or S3I-201 [49] inhibitors in the NSCLC lines with high Src418 showed that this treatment did not increase GJIC (e.g., line A549, Figure 2B) [33,38], in agreement with observations from T51B-Src cells [36], indicating that Stat3 is not part of a Src pathway to GJIC suppression. Here, SRC is linked to non-small cell lung carcinoma.